A case report of eosinophilic myocarditis and a review of the relevant literature by unknown
Li et al. BMC Cardiovascular Disorders  (2015) 15:15 
DOI 10.1186/s12872-015-0003-7CASE REPORT Open AccessA case report of eosinophilic myocarditis and a
review of the relevant literature
Haiying Li, Zhenyu Dai, Binqiao Wang and Weijian Huang*Abstract
Background: Eosinophilic myocarditis (EM) is a relatively rare condition that may result from parasitic infections
and allergic disease. Antituberculosis drugs may lead to focal myocardial infiltration by eosinophils (eosinophilic
myocarditis). Symptoms may be severe, and, lead to rapidly-fatal outcomes. Early diagnosis and high-dose
corticosteroids are the cornerstone of treatment, and, may lead to restoration of cardiac function with full recovery.
Case presentation: We report a case of eosinophilic myocarditis secondary to eosinophilia caused by antituberculosis
drugs with markedly elevated ECP, focal eosinophilic infiltration in CMR imaging and endomyocardial biopsy. Finally,
high-dose corticosteroids were used to reverse the cardiac injury and to improve the clinical outcome.
Conclusion: Antituberculosis drugs can cause eosinophilic infiltration of, and damage to, the myocardium leading to
rapid progression of the clinical symptoms. Myocardial biopsy is helpful in diagnosing the disease in the early stages
and high-dose corticosteroids effectively improves the prognosis of this disease.
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Eosinophilic cells (EC) constitute 0% to 7% (0.05–0.45 ×
109/L) of normal leukocytes; however, the exact function
of this cell type remains to be fully elucidated. ECs par-
ticipate in normal immune responses although abnormal
increases in this population can cause tissue damage.
ECs contain cytotoxic granules with an array of cationic
proteins including eosinophilic cationic protein (ECP),
eosinophil peroxidase, and eosinophil-derived neuro-
toxin as well as numerous RNases, and produce reactive
oxygen species such as peroxidase, elastase, cytokines.
Following activation of ECs by an immune stimulus,
these substances are released by degranulation to medi-
ate tissue damage and dysfunction. ECs have surface
proteins that specifically bind IgE complexed with anti-
gen to induce phagocytosis and degranulation [1].
A definitive diagnosis of eosinophilic myocarditis(EM)
[2] eosinophilic myocarditis is made on the basis of two
criteria: fulfillment of the four criteria for diagnosis of
carditis (ECG or Holter or stress test features, elevated
troponin T (TnT) or troponin I (TnI) markers of myo-
cardiocytolysis, functional and structural abnormalities* Correspondence: wangbinqiao@hotmail.com
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unless otherwise stated.in cardiac imaging and cardiac magnetic resonance
(CMR) tissue characterization and a histological diagno-
sis based on the type of inflammatory cell infiltrate. EM
is a relatively rare condition that may occur in a variety
of settings including parasitic infections and allergic dis-
ease. The best known form of this disease is the Loeffler
endomyocardial fibrosis, which occurs as a major com-
plication of idiopathic hypereosinophilic syndrome. Ex-
tensive myocarditis can be caused by parasites, leading
to high mortality, and in some cases is caused by drug
reactions and allograft rejection in heart transplantation.
In addition, Churg-Strauss Syndrome can produce myo-
cardial granulomas and extensive myocardial lesions can
cause heart failure, progressing to dilated cardiomyop-
athy (DCM) in some patients. Among the inflammatory
cells that infiltrate the cardiac tissue, which is secondary
to these types of diseases, the damage caused by EC is
significant [3]. The aim of this study was to increase
recognition of EM and the use of endomyocardial biopsy
(EMB)The use of endomyocardial biopsy(EMB), which is
the gold standard in Europe, for effective identification
of cases caused by EC infiltration in response to allergic
reactions to antituberculosis drugs. To address this issue,
we present a clinical case of myocardial damageis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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comprehensive investigation of the relevant case presen-
tations, diagnosis, and treatment reported in the litera-
ture to improve early diagnosis for the timely initiation
of clinical treatment of myocardial lesions caused by
eosinophilia.
Case presentation
On March 6, 2012, a 43-year-old Chinese businessman
with a 5-year medical history of hypertension presented
with recurrent chest pain and chest tightness commen-
cing six months prior to his admission to the Cardiology
Department of the First Affiliated Hospital of Wenzhou
Medical University. The patient denied any history food
and drug allergies and endemic water exposure.
On January 16, 2012, the patient had been admitted to
our hospital for treatment of fever, persistent severe
headaches with chills, nausea and vomiting. On admis-
sion, his temperature was 39°C, he had nuchal rigidity
and was Kernig sign positive but Brudzinski sign negative,
with other components of his physical examination found
to be non-contributory. Laboratory tests of CSF showed
the following: WBC, 146/μL; LY, 91%; Pandy test positive;
Pro, 2,767 mg/L; Glu, 1.9 mmol/L; Cl− 106, mmol/L.
Intracranial infection was clinically suspected, with tuber-
culous meningitis primarily considered; therefore, the pa-
tient was administered the standard tuberculosis control
regimen of isoniazid, rifampicin, pyrazinamide and etham-
butol (HRZE). During the course of treatment, however,
rifampicin (RFP) was discontinued due to impaired hep-
atic function. The patient was then started on diammo-
nium glycyrrhizinate treatment, which gradually improved
the hepatic function. Eventually, the patient’s condition
stabilized, his temperature normalized and the symptoms
were markedly resolved. He was discharged 50 days later
with continued HZE medication.
On March 6, 2012, the patient was again hospitalized
complaining of persistent chest tightness and chest pain
which progressed dramatically. His temperature was
38.6°C with no chills, coughing or dyspnea at that time.
Chest CT imaging indicated a small amount of pericar-
dial effusion but no pulmonary infiltration. Laboratory
data revealed the following: platelet count, 36 × 109/L;
eosinophils 3.0 × 109/L; Tn, 7.23 ng/mL; creatine kinase-
MB (CK-MB), 44 U/L.
After hospitalization, the patient’s blood pressure
decreased gradually to approximately 90/60 mmHg
(1 mmHg is equal to 0.133 kPa) with dopamine treat-
ment (3–8 μg/kg/min). His urine volume remained nor-
mal and his extremities were warm. During the first
three days in hospital, the patient’s myocardial enzymes
continued to elevate, with Tn rising to 50.0 ng/ml, CK
reaching 410 U/L and CK-MB increasing to 52 U/L.
Routine blood tests showed marked EC elevation(5.0 × 109/L). In addition, flat or inverted T waves in
leads V3–V6 were observed in ECG (Figure 1).
During the diagnostic investigation of etiology, add-
itional laboratory analyses including repeated blood
cultures, blood tumor series and autoimmune series,
provided no evidence of hematogenous infection or
autoimmune diseases. Bone marrow aspiration cytology
showed myeloproliferation, elevated ECs and megakar-
yoblast hyperplasia with disordered maturation. There
were no abnormal cells and hematopathy was excluded.
Comparison with the patient’s previous CSF results
showed that his infection was relatively controlled.
On March 12, 2012, echocardiography showed that
the patient had normal movement of the ventricular wall
but impaired diastolic function (left ventricular end
diastolic diameter (LVEDD), 47 mm; interventricular
septum thickness (IVS), 12 mm; left ventricular ejection
fraction (LVEF), 50.8%).
On March 13, 2012, coronary angiography showed that
there was no stenosis or obstructive lesions in the coron-
ary artery. Left ventricular angiography revealed thickening
of the apical ventricular membrane (Figure 2). Swan-Ganz
catheterization indicated normal systolic function with dis-
ordered cardiac diastolic function, which recovered sub-
stantially after blood pressure stabilization treatment and
adequate fluid infusion (Table 1).
Repeated head MRIs revealed the continued presence
of meningeal infiltration and no obvious improvement
in the parenchymal nodules in the brain (Figure 3).
Cardiac MRI showed significant enhancement of an
irregular stripe signal after left ventricular subendocar-
dial enhancement in the delay period and abnormal en-
hancement of patch and stripe signal in the ventricular
septum (Figure 4).
Based on these findings, with particular reference to
the significant increase in the peripheral eosinophil
count in the present case, a diagnosis of systemic disease
resulting in focal eosinophilic infiltration and severe
myocardial damage was initially postulated. To confirm
the final diagnosis, the patient underwent an EMB,
which showed obvious diffuse EC infiltration without
focal necrosis (Figure 5). Electron microscopy exhibited
extensive myocardial interstitial infiltration by EC ac-
companied by focal myocardial fiber cracking and disin-
tegration (Figure 5).
At 11:00 pm on the March 15, 2012, the patient pre-
sented with chest tightness, fatigue, irritability, fever and
chills, with a body temperature of 39°C. Subsequently,
his blood pressure declined, followed by respiratory and
cardiac arrest. After immediate chest compression, de-
fibrillation and tracheal intubation, the patient’s circula-
tion was recovered successfully.
On March16, 2012, methylprednisolone pulse therapy
(80 mg) was administered and the patient’s EC levels
Figure 1 The dynamic changes of ECG. T waves in leads V3–V6 observed in ECG were flat or inverted.
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to 2.0 × 109/L on the third day. On March 17, 2012, the
patient was extubated and conscious and his cardiac
function markedly improved. The final diagnosis of eo-
sinophilic myocarditis was confirmed and steroid treat-
ment was started with methylprednisolone pulse therapyFigure 2 Echocardiography and left ventricular angiography. A. Echoc
deteriorated diastolic function (left ventricular end diastolic diameter (LVED
ventricular ejection fraction (LVEF), 50.8%). Coronary angiography showed t
B. Left ventricular angiography showed thickening of the apical ventricular(500 mg) daily for the first three days and a maintenance
dose of 60 mg for the next seven days. The patient
continued to receive a dose of 1 mg/kg/d, which was
gradually reduced to 5 mg every two weeks in the long-
term follow-up visits. Metoprolol sustained-release
tablets (47.5 mg/d), perindopril tablets (2 mg/d) andardiography revealed normal movement of the ventricular wall and
D), 47 mm; interventricular septum thickness (IVS), 12 mm; left
hat there was no stenosis or obstructive lesions in the coronary artery;
membrane.
Table 1 Swan-Ganz catheter measurements
CO L/min CI L/min*m2 CVP mmHg PCWP mmHg PA mmHg SVR DS/cm SVRI DS/cm PVR DS/cm2 PVRI DS*m2/cm2
03.13 4.7 2.8 5 18 20 1116 1752 36 57
16:00
03.13 3.75 2.4 9 18 20 1173 1798 43 65
19:00
03.13 3.98 2.6 7 15 18 1186 1819 141 216
21:00
03.14 3.76 2.4 11 22 24 1277 2005 64 100
14:30
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also administered. On April 25, 2012, the patient was
healthy enough to be discharged from the hospital. The
follow-up data of the patient showed normalized EC, re-
turn of PLT to standard levels and complete recovery of
cardiac function.Figure 3 Head MRI. A. Head MRI taken on February 24; B. Head MRI taken
the continued presence of meningeal infiltration and no obvious improvemDiscussion
EM is a rare form of myocarditis characterized patho-
logically by diffuse focal myocardial inflammation with
eosinophilic infiltration, often in association with periph-
eral blood eosinophilia [4]. In this case, we suspected
focal eosinophilic infiltration following CMR imagingon March 13. Comparison of the results of the head MRIs revealed
ent in the parenchymal nodules in the brain.
Figure 4 Cardiac magnetic resonance (CMR) imaging. CMR imaging showed significant enhancement of an irregular stripe signal after left
ventricular subendocardial enhancement in the delay period and abnormal enhancement of patch and stripe signal in the ventricular septum.
Li et al. BMC Cardiovascular Disorders  (2015) 15:15 Page 5 of 8and confirmed them by endomyocardial biopsy. We used
high-dose corticosteroids to reverse the cardiac injury
and to improve the clinical outcome .In the current case
presentation, the laboratory features of focal eosinophilic
infiltration were observed in both CMR imaging and
endomyocardial biopsy. This evidence of marked cardiac
damage led to a rapid diagnosis of eosinophilic myocar-
ditis, which was critical for timely and appropriate ster-
oid therapy. This treatment strategy was based on
previously documented cases from abroad, which re-
ported that the use of steroids is predictably effective in
the early stages to reverse cardiac injury and to improve
the prognosis of patients with eosinophilic myocarditis.
Different etiologies for eosinophilic myocarditis have
been described including hypereosinophilic syndrome,
Loeffler endocarditis and tropical endomyocardial fibro-
sis. Myocarditis due to hypersensitivity to medication
and numerous drugs have been implicated as the most
common cause [5]. Eosinophilia is generally secondary
to the effects of an array of pathogens, and the usage of
tuberculosis drugs such as isoniazid, rifampicin and pyr-
azinamide have been implicated in previous case reports
of EM.
At the cellular level, the mechanism of EM involves
activation-stimulated eosinophilic degranulation of a
number of compounds, especially eosinophilic cationic
proteins that mediate myocardial tissue damage, even-
tually leading to eosinophilic myocarditis.
According to previous reports [6-8], Cardiac involve-
ment occurs in 54–82% of cases, and, the prognosis is
determined by the extent of the endocardial fibrosis andrelated complications. The five year mortality of EM is
30%.
The proposed mechanism of EM in association with
abnormally high EC counts is characterized predomi-
nantly by diffuse or focal eosinophilic infiltration of the
myocardium. This infiltration plays a vital role in the
pathogenesis of eosinophilic myocarditis via release of
eosinophilic granule proteins such as ECP and major
basic protein (MBP), which causes dysfunction of myo-
cyte mitochondria leading to myocardial lesions [9], as
well as endocardial necrosis [10].
Myocarditis presents in many different ways, ranging
from mild symptoms of chest pain and palpitations asso-
ciated with transient ECG changes, to life-threatening
cardiogenic shock and ventricular arrhythmia [2]. As an
acute inflammatory response with abundant eosinophils,
myocytolysis may develop, as well as endomyocardial
thrombi, necrotizing vasculitis, pericarditis, pericardial
fibrosis and endomyocardial fibrosis [11]. Studies [11,12]
have also indicated that cardiac failure, arterial em-
bolism, endomyocardial thickening and left ventricular
lateral thrombosis are the most common presentations
of eosinophilic myocarditis with cardiac involvement.
Cardiac involvement evolves in three stages [13], the
first stage being the acute necrotic stage. At this stage,
during which most patients are asymptomatic, myocar-
ditis is characterized by cellular infiltration and inflam-
mation as well myocardial necrosis and, in some cases,
eosinophilic granulomas [14]. The second or thrombotic
stage, also known as the mural thrombus stage, is
characterized by the formation of intracardiac mural
Figure 5 Endomyocardial biopsy and cardiac electrogram. Endomyocardial biopsy (A and B) showed there was obvious infiltration of EC
and focal necrosis. Electron microscopy (C, D and E) revealed extensive myocardial interstitial infiltration by EC accompanied by focal myocardial
fiber cracking and disintegration Internal scales: A: 100 μm; B: 50 μm; C, D and E: 1 μm.
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The third and of fibrotic stage is characterized by fibro-
sis of the thrombus-damaged myocardium. This is the
final pathological stage of the disease, which eventually
leads to restrictive cardiomyopathy as well as atrioven-
tricular valve dysfunction [15].
Accurate assessment of eosinophilic myocarditis is
limited by difficulties in establishing the diagnosis, which
is made on the basis of medical history, clinical presen-
tation, and laboratory findings. In some cases, it is diffi-
cult to differentiate myocarditis from acute myocardial
infarction due to similar presentations and lack of spe-
cific evidence; thus, the diagnosis process can impede
the timely treatment of eosinophilic myocarditis in the
early stages [16]. This is critical for the prevention of the
rapid clinical progression and high mortality associated
with eosinophilic myocarditis. However, current tech-
niques provide extremely limited ability to establish a
definitive diagnosis, as well as to monitor the course of
the disease.The marked elevation of eosinophil counts, although
not specific, supports the diagnosis of eosinophilic myo-
carditis, and some studies [10,17] have indicated that the
number of degranulated eosinophils and serum ECP
levels can be valuable and objective parameters for mon-
itoring disease activity, particularly after treatment. In
addition, coronary angiograms can be used to exhibit
thrombus formation and subsequent blockage of the
coronary vessels [18].
CMR imaging is reported by Debl et al. [19] as the
only noninvasive method that can be used prior to EMB
to visualize the extent of endomyocardial involvement in
the early diagnosis of eosinophilic myocarditis as well as
in the assessment during treatment. Mavrogeni et al.
[20] also reported CMR, as an emerging role to evaluate
the Kawasaki disease(KD) which is a specific type of sys-
temic vasculitis, can image myocardial inflammation,
myocardial perfusion, ventricular function and fibrosis,
offering crucial detailed clinical information for diagno-
sis of EM.
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edema, and pericardial effusion toward the cardiac apex
are frequent findings, is not routinely recommended for
the diagnosis of myocarditis, due to its limited availa-
bility and risk of radiation exposure [2].
The concept that EMB is the gold standard for a de-
finitive diagnosis of myocarditis is strongly endorsed
despite its limited sensitivity and specificity [21,22].
EMB findings are characterized by diffuse myocardial
necrosis associated with extensive eosinophilic infiltra-
tion of the myocardial interstitium, focal myocyte dissol-
ution, perivascular infiltration and myocardial interstitial
fibrosis [23].
The therapy of choice after a diagnosis EM consists of
standard heart failure medication and early treatment with
high doses of cortisone [24]. The early initiation of steroid
therapy can achieve substantial improvements in clinical
outcomes, prognosis and long-term survival [25]. In three
cases presented by Wong et al. [26], all the patients de-
monstrated complete recovery and normalization of
cardiac contractility after treatment with high-dose oral
steroids with gradual tapering. Left ventricular assist de-
vice (LVAD) support [27] is a useful option for refractory
conditions in cases of heart failure or arrhythmia. This
technology has been successfully used to bridge patients
with acute myocarditis to recovery as well as in the transi-
tion of patients awaiting heart transplantation.
Conclusion
In summary, myocarditis presents in a variety of ways and
EM should be considered in cases with eosinophil eleva-
tion. In this case, the results of relevant laboratory analyses
and several clinical features correlating with the use of anti-
tuberculosis drugs led to the suspicion of EM. This diagno-
sis was supported by EMB and CMR imaging results. Swift
diagnosis with rapid initiation of steroid treatment achieved
good clinical effect and complete resolution of EM as well
as marked improvement in the patient’s prognosis.
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